RARE vs. ARWR, PRGO, ACAD, BHC, MRTX, VTRS, UTHR, RDY, SRPT, and CTLT
Should you be buying Ultragenyx Pharmaceutical stock or one of its competitors? The main competitors of Ultragenyx Pharmaceutical include Arrowhead Pharmaceuticals (ARWR), Perrigo (PRGO), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Viatris (VTRS), United Therapeutics (UTHR), Dr. Reddy's Laboratories (RDY), Sarepta Therapeutics (SRPT), and Catalent (CTLT). These companies are all part of the "pharmaceutical preparations" industry.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, media sentiment, dividends, analyst recommendations, community ranking and valuation.
62.6% of Arrowhead Pharmaceuticals shares are held by institutional investors. Comparatively, 97.7% of Ultragenyx Pharmaceutical shares are held by institutional investors. 4.5% of Arrowhead Pharmaceuticals shares are held by insiders. Comparatively, 5.8% of Ultragenyx Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Ultragenyx Pharmaceutical received 286 more outperform votes than Arrowhead Pharmaceuticals when rated by MarketBeat users. Likewise, 77.14% of users gave Ultragenyx Pharmaceutical an outperform vote while only 65.26% of users gave Arrowhead Pharmaceuticals an outperform vote.
In the previous week, Ultragenyx Pharmaceutical had 9 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 17 mentions for Ultragenyx Pharmaceutical and 8 mentions for Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals' average media sentiment score of 0.99 beat Ultragenyx Pharmaceutical's score of 0.76 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.
Arrowhead Pharmaceuticals presently has a consensus price target of $51.00, indicating a potential upside of 122.22%. Ultragenyx Pharmaceutical has a consensus price target of $90.67, indicating a potential upside of 125.88%. Given Arrowhead Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Ultragenyx Pharmaceutical is more favorable than Arrowhead Pharmaceuticals.
Arrowhead Pharmaceuticals has a beta of 0.78, indicating that its stock price is 22% less volatile than the S&P 500. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.68, indicating that its stock price is 32% less volatile than the S&P 500.
Ultragenyx Pharmaceutical has a net margin of -138.58% compared to Ultragenyx Pharmaceutical's net margin of -163.32%. Ultragenyx Pharmaceutical's return on equity of -140.72% beat Arrowhead Pharmaceuticals' return on equity.
Arrowhead Pharmaceuticals has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Ultragenyx Pharmaceutical, indicating that it is currently the more affordable of the two stocks.
Summary
Ultragenyx Pharmaceutical beats Arrowhead Pharmaceuticals on 13 of the 18 factors compared between the two stocks.
Get Ultragenyx Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for RARE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RARE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ultragenyx Pharmaceutical Competitors List
Related Companies and Tools
